静脉注射Ibuprofen市场：依适应症、强度、年龄层、通路、地区

预计到 2024 年，全球静脉注射 (IV)Ibuprofen市场规模将达到 69.1 亿美元，到 2031 年将达到 111.3 亿美元，2024 年至 2031 年复合年增长率为 7%。

图：2024 年按地区分類的静脉注射 (IV)Ibuprofen市场占有率(%)

静脉注射 (IV)Ibuprofen几十年来一直用于缓解疼痛和退烧。作为非类固醇消炎剂(NSAID)Ibuprofen的静脉注射製剂，吸收和起效比口服给药更快。静脉注射（IV）Ibuprofen的作用是抑制Gland的产生，前列腺素是体内促进疼痛和发烧的荷尔蒙物质。静脉注射时，可在15分钟内缓解中度至重度疼痛，单剂量可持续长达8小时。近年来，由于需要静脉注射疼痛管理的疾病数量不断增加，以及与其他镇痛药物相比的优势，全球静脉注射（IV）Ibuprofen市场近年来稳步增长。

市场动态：

患有整形外科疾病和术后疼痛的老年人数量不断增加，发烧和疼痛疾病的盛行率不断增加，以及静脉注射（IV）Ibuprofen相对于口服非类固醇抗发炎药（NSAID）的优越疗效，这些都推动了静脉注射（IV）Ibuprofen的成长。然而，长期使用和偏好非鸦片类替代品的消化道出血和肾毒性的潜在风险预计将抑制市场成长。随着评估新适应症和剂型功效的临床试验正在进行，我们预计将带来利润丰厚的商机。

本研究的主要特点

• 本报告详细分析了全球静脉（IV）Ibuprofen市场，并介绍了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%） 。
• 它还说明了各个细分市场的潜在商机，并为该市场提供了一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
• 本报告根据公司亮点、产品系列、主要亮点、业绩和策略等参数，介绍了全球静脉（IV）Ibuprofen市场的主要参与者。
• 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球静脉注射 (IV)Ibuprofen市场迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 透过用于分析全球静脉（IV）Ibuprofen市场的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与前提

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章 市场动态、法规与趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 最近的趋势
• 监管场景
• 製造商收益
• 价格分析
• 收购和合作场景
• 产品发布/核准
• 资金筹措和投资
• PEST分析
• 波特的分析

第 4 章全球静脉 (IV)Ibuprofen市场，COVID-19 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章全球静脉（IV）Ibuprofen市场，依适应症分类，2019-2031

• 疼痛管理
• 热
• 其他的

第六章 全球静脉 (IV)Ibuprofen市场，依实力划分，2019-2031

• 100mg
• 200mg
• 400mg
• 800mg

第七章全球静脉（IV）Ibuprofen市场，依年龄组别，2019-2031

• 小儿科
• 成人

第8章全球静脉（IV）Ibuprofen市场，依通路划分，2019-2031

• 医院药房
• 零售药房
• 网路药房

第9章2019-2031年全球静脉（IV）Ibuprofen市场（按地区）

第10章竞争格局

• 公司简介
  • Cumberland Pharmaceuticals Inc.
  • Hyloris Pharmaceuticals SA
  • Grifols, SA
  • Recordati Rare Diseases Inc.
  • XGEN PHARMACEUTICALS DJB, Inc.
  • AFT Pharmaceuticals
  • Laboratorios Valmorca
  • SGPharma Pvt. Ltd.
  • Wellona Pharma
  • Delex Pharma
  • Hikma Pharmaceuticals PLC

第十一章分析师建议

• 分析师观点
• 一致的机会图

第十二章参考文献与调查方法

• 参考
• 调查方法

Global intravenous (IV) ibuprofen market is estimated to be valued at USD 6.91 Bn in 2024 and is expected to reach USD 11.13 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7% from 2024 to 2031.

Figure. Intravenous (IV) Ibuprofen Market Share (%), By Region 2024

Intravenous (IV) ibuprofen is used for pain relief and fever reduction for several decades. As an intravenous formulation of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen, it offers faster absorption and onset of action as compared to oral administration. Intravenous (IV) ibuprofen works by blocking the production of prostaglandins - hormone-like substances in the body that promote pain and fever. With intravenous delivery, it can provide relief for moderate to severe pain within 15 minutes and may be effective for up to 8 hours with a single dose. Global intravenous (IV) ibuprofen market has witnessed steady growth in recent years due to increasing prevalence of diseases requiring IV pain management and benefits over other analgesic options.

Market Dynamics:

Global intravenous (IV) ibuprofen market growth is driven by rising geriatric population suffering from orthopedic diseases and postoperative pain, growing prevalence of fever and pain conditions, and superior efficacy of IV ibuprofen over oral NSAIDs. However, potential risks of gastrointestinal bleeding and kidney toxicity with long-term use along with preference for non-opioid alternatives are expected to restrain the market growth. Ongoing clinical trials evaluating efficacy for new indications and formulations present lucrative opportunities.

Key Features of the Study:

• This report provides in-depth analysis of the global intravenous (IV) ibuprofen market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global intravenous (IV) ibuprofen market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A., Recordati Rare Diseases Inc., XGEN PHARMACEUTICALS DJB, Inc., AFT Pharmaceuticals, Laboratorios Valmorca, SGPharma Pvt. Ltd., Wellona Pharma, Delex Pharma, and Hikma Pharmaceuticals PLC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global intravenous (IV) ibuprofen market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global intravenous (IV) ibuprofen market.

Detailed Segmentation-

• By Indication:
  • Pain Management
  • Fever
  • Others
• By Strength:
  • 100 mg
  • 200 mg
  • 400 mg
  • 800 mg
• By Age Group:
  • Pediatrics
  • Adults
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Cumberland Pharmaceuticals Inc.
  • Hyloris Pharmaceuticals SA
  • Grifols, S.A.
  • Recordati Rare Diseases Inc.
  • XGEN PHARMACEUTICALS DJB, Inc.
  • AFT Pharmaceuticals
  • Laboratorios Valmorca
  • SGPharma Pvt. Ltd.
  • Wellona Pharma
  • Delex Pharma
  • Hikma Pharmaceuticals PLC

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Indication
  • Market Snapshot, By Strength
  • Market Snapshot, By Age Group
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Regulatory Scenario
• Manufacturer Revenue
• Pricing Analysis
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Fundings and Investments
• PEST Analysis
• Porter's Analysis

4. Global Intravenous (IV) Ibuprofen Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Intravenous (IV) Ibuprofen Market, By Indication, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pain Management
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Fever
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Intravenous (IV) Ibuprofen Market, By Strength, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• 100 mg
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• 200 mg
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• 400 mg
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• 800 mg
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Intravenous (IV) Ibuprofen Market, By Age Group, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Pediatrics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Adults
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Intravenous (IV) Ibuprofen Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Intravenous (IV) Ibuprofen Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • Cumberland Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Hyloris Pharmaceuticals SA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Grifols, S.A.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Recordati Rare Diseases Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • XGEN PHARMACEUTICALS DJB, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AFT Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Laboratorios Valmorca
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • SGPharma Pvt. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Wellona Pharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Delex Pharma
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Hikma Pharmaceuticals PLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact